S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
NASDAQ:SAGE

Sage Therapeutics (SAGE) Stock Price, News & Analysis

$13.33
+0.29 (+2.22%)
(As of 04/19/2024 ET)
Today's Range
$12.93
$13.61
50-Day Range
$12.57
$25.75
52-Week Range
$10.92
$59.99
Volume
1.26 million shs
Average Volume
1.00 million shs
Market Capitalization
$801.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.28

Sage Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.12 Rating Score
Upside/​Downside
194.7% Upside
$39.28 Price Target
Short Interest
Bearish
17.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.66
Upright™ Environmental Score
News Sentiment
-0.26mentions of Sage Therapeutics in the last 14 days
Based on 41 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.06) to ($4.32) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.95 out of 5 stars

Medical Sector

185th out of 908 stocks

Pharmaceutical Preparations Industry

67th out of 399 stocks

SAGE stock logo

About Sage Therapeutics Stock (NASDAQ:SAGE)

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SAGE Stock Price History

SAGE Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $17.00
Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $16.00
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Sage Therapeutics (NASDAQ:SAGE) Rating Reiterated by Wedbush
Sage Therapeutics (SAGE) Scheduled to Post Earnings on Thursday
Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge
See More Headlines
Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
4/20/2024
Next Earnings (Confirmed)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SAGE
Employees
487
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.28
High Stock Price Target
$294.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+194.7%
Consensus Rating
Hold
Rating Score (0-4)
2.12
Research Coverage
17 Analysts

Profitability

Net Income
$-541,490,000.00
Net Margins
-626.32%
Pretax Margin
-626.33%

Debt

Sales & Book Value

Annual Sales
$86.46 million
Book Value
$13.32 per share

Miscellaneous

Free Float
56,801,000
Market Cap
$801.27 million
Optionable
Optionable
Beta
0.86
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Barry E. GreeneMr. Barry E. Greene (Age 61)
    President, CEO & Director
    Comp: $1.29M
  • Ms. Kimi E. Iguchi CPA (Age 62)
    CFO & Treasurer
    Comp: $665.37k
  • Ms. Anne Marie Cook Esq. (Age 62)
    Senior VP, General Counsel & Secretary
    Comp: $711.6k
  • Mr. Christopher Benecchi (Age 52)
    Chief Business Officer
    Comp: $703.76k
  • Dr. Laura Gault M.D.
    Ph.D., Chief Medical Officer
  • Mr. Matt Lasmanis
    Chief Technology & Innovation Officer
  • Mr. Mike Quirk
    Chief Scientific Officer
  • Ashley Kaplowitz
    Director of Investor Relations
  • Ms. Erin E. Lanciani (Age 55)
    Chief People & Experience Officer
  • Dr. Amy Schacterle Ph.D.
    Senior Vice President of R&D Strategy and Business Management

SAGE Stock Analysis - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 1 sell rating, 13 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings
or view top-rated stocks.

What is Sage Therapeutics' stock price target for 2024?

17 analysts have issued 1-year price objectives for Sage Therapeutics' shares. Their SAGE share price targets range from $14.00 to $294.00. On average, they predict the company's stock price to reach $39.28 in the next year. This suggests a possible upside of 194.7% from the stock's current price.
View analysts price targets for SAGE
or view top-rated stocks among Wall Street analysts.

How have SAGE shares performed in 2024?

Sage Therapeutics' stock was trading at $21.67 at the beginning of 2024. Since then, SAGE shares have decreased by 38.5% and is now trading at $13.33.
View the best growth stocks for 2024 here
.

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our SAGE earnings forecast
.

How can I listen to Sage Therapeutics' earnings call?

Sage Therapeutics will be holding an earnings conference call on Thursday, April 25th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its quarterly earnings data on Wednesday, February, 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($1.28) by $0.73. The biopharmaceutical company earned $77.97 million during the quarter, compared to analysts' expectations of $60.15 million. Sage Therapeutics had a negative net margin of 626.32% and a negative trailing twelve-month return on equity of 54.41%. The company's revenue for the quarter was up 2621.5% on a year-over-year basis. During the same period in the prior year, the business earned ($2.47) earnings per share.

What ETFs hold Sage Therapeutics' stock?

ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL) and Virtus LifeSci Biotech Products ETF (BBP).AdvisorShares Dorsey Wright Short ETF (DWSH).

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.11%) and Allspring Global Investments Holdings LLC (0.08%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends
.

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SAGE) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners